Replies to post #102177 on Arrayit Corporation (ARYC)

[PennyStock Alert]

OvaDx® is an advanced microarray-based diagnostic test that measures the activation of the immune system in response to ovarian tumor cell development. Patient sera are applied to OvaDx® microarrays to allow binding between proteomic biomarkers in the patient samples and capture agents on the microarrays. The microarrays are washed and scanned to produce a digital readout for each serum sample, and the data are quantified and analyzed in software to generate the test results. Clinicians will appreciate the following feaures of this product:

Market’s first large panel monitoring test for ovarian cancer
Use an elective screen for women seeking greater wellness
Screen women at elevated risk for ovarian cancer
High sensitivity and specificity for all types and stages of ovarian cancer
Research studies based on the screening of 257 total samples
79.7% combined sensitivity based on 55 of 69 OVC samples scored as positive
Specificity determined by screening 178 samples from healthy patients and 10 samples from patients with benign gynecological conditions
100% specificity based on 188 of 188 non-OVC samples scored as negative
Identifies stage I, II, III and IV disease markers in patient samples
Detects stage IA disease markers with ~80% sensitivity
Detects borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous, and ovarian adenocarcinoma in patient sera
Multi-plexed microarray assay reads approximately 100 proteomic biomarkers
Proteomic panel provides definitive real-time test results
Microarray format reduces serum requirement to 0.1-0.25 ml per sample run
Blood cards can be used for sample collection
Fluorescence detection ensures high signal detectivity
Test controls eliminate experimental false positives and false negatives
High-throughput format scales to any number of patient samples
Automated process permits large-scale (e.g. 1,000,000 sample+) screening
Supplement OVA1® and other multi-analyte tests
Supplement single marker tests including cancer antigen 125 (CA-125) and human epididymis protein (HE4)
Supplement genetic tests including BRCA1 and BRCA2
Supplement imaging techniques including transvaginal ultrasound, computerized tomography (CT) scans, and x-rays
Screen patient sera from breast, cervical, uterine and other cancer patients
Test samples from patients with ovarian cysts and other benign conditions

[Sloan89RH]

RBW and Cary, i agree with your observation and it should fall into the foot-stomper category. Some of the Tweets have been denigrated by various posters; however, the validity of the Tweets have not been dis-proven.